ONTX
- Onconova Therapeutics, Inc.
()
Overview
Company Summary
Onconova Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of cancer and other critical diseases. The company is primarily engaged in conducting clinical trials and research to develop innovative drugs that target key molecular pathways involved in cancer growth and progression.
Onconova's main focus is onnovel targeted small molecules known as Rigosertib and ON 123300, which are being evaluated as potential treatments for various types of cancer, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and solid tumors. Rigosertib, in particular, is a unique target therapy that inhibits a specific enzyme related to cancer cell survival and proliferation.
In addition to its proprietary drug candidates, Onconova also collaborates with academic institutions, research organizations, and pharmaceutical companies to develop and commercialize innovative therapies. These collaborations help the company leverage external expertise, resources, and funding to advance its pipeline and bring potential treatments to market.
Overall, Onconova Therapeutics is dedicated to addressing the unmet medical needs of cancer patients by developing and advancing novel therapies that have the potential to improve outcomes and quality of life.